TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06175676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxybutyl chitosan
Description: Apply HBCS to the anastomosis of the nasal mucosal flap and the dacryocyst mucosal flap

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxybutyl chitosan
Description: Apply HBCS to the anastomosis of the nasal mucosal flap and the dacryocyst mucosal flap

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Inject 0.3ml of 5-FU solution (25mg/ml) into the nasal mucosa around the anastomosis, and apply HBCS to the anastomosis of the nasal mucosal flap and the dacryocyst mucosal flap

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin Sponge Sheet
Description: Apply gelatin sponge sheet covered with thrombin and tobramycin and dexamethasone ophthalmic ointment to the anastomosis of nasal mucosal flap and dacryocyst mucosal flap
Study: NCT04523688

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cells (DC) vaccine
Description: 10×10exp6 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Adjuvant temozolomide assumed orally from day 1 to 5 (start on week 5). Dosage: 150mg/m2/day for the first cycle and 200 mg/m2/day for subsequent cycles (q28).
Study: NCT05484804

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data Accountability and Transparency
Description: Collaboration with Practice Facilitators; Maternal Early Warning System; Disparities Dashboard; Racial Equity Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data Accountability and Transparency
Description: Collaboration with Practice Facilitators; Maternal Early Warning System; Disparities Dashboard; Racial Equity Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community-Based Doula (CBD) Support
Description: Community-Based Doula support for high-risk patients; Racial Equity Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community-Based Doula (CBD) Support
Description: Community-Based Doula support for high-risk patients; Racial Equity Training
Study: NCT05544162

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition supplement - Ensure shakes
Description: Ensure shakes will be take up to 3 times a day throughout hospitalization and for 4 weeks after discharge.
Study: NCT04940299

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Given SC
Study: NCT05329246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-assisted Clinical Assistant PMcardio
Description: PMcardio is an AI-powered clinical assistant in the form of a mobile application empowering non-cardiologist healthcare workers with advanced cardiovascular diagnostic capabilities, recommending patient-specific suggestions for referral and facilitating remote consultations with specialized cardiologists.
Study: NCT04496817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid and Lutein Enriched Eggs
Description: Consumption of 2 docosahexaenoic acid and lutein enriched eggs daily (at least 5 days our week) for 6 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular Eggs
Description: Consumption of 2 non enriched eggs daily (at least 5 days our week) for 6 weeks
Study: NCT05221931

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: 1:1 randomization to DES (Ultimaster Tansei) or DCB (Agent \[Boston Scientific, USA\], Prevail \[Medtronic, USA\], or SeQuent Please, SeQuent Please NEO \[B-Braun, Germany\])

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: 1:1 randomization to DES (Ultimaster Tansei) or DCB (Agent \[Boston Scientific, USA\], Prevail \[Medtronic, USA\], or SeQuent Please, SeQuent Please NEO \[B-Braun, Germany\])
Study: NCT04990024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention Med Diet
Description: The diet will consist of a calorie-restricted Med diet, with 500 Kcal/d energy restriction. The intervention consists of individual and reinforcement sessions on Med diet. During these sessions, the RA will go over the benefits of Med diet, what composition it should have, and how to make appropriate choices for meal planning, in addition to providing food lists, by season. The individual sessions with subjects will also allow to individualize the diet plan.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention HP/LC Diet
Description: This is a non-ketogenic diet consisting of ad libitum intake of proteins, fat, and vegetables, with restriction of daily carbohydrates to \<130 g/d. The intervention consists of individual and reinforcement educational sessions on HP/LC, same as with Med diet (above). The individual sessions with subjects will also allow to individualize the diet plan.
Study: NCT05057611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRT-targeted strategy associated with a clinical hemodynamic phenotyping to personalize initial resuscitation in septic shock patients
Description: A combination of combine a CRT-targeted strategy with a clinical hemodynamic phenotyping that may aid to personalize initial resuscitation with potential additional fluid-sparing effects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (UC)
Description: - Patients allocated to the UC group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP \>65 mmHg, heart rate (HR) \<120 beats per minute (BPM), arterial oxygen saturation (SaO2) \>94%, Hb \> 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
Study: NCT05711810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 MG
Description: Due to initial availability of drugs and the intensities of the patient's symptoms, Nifedipine was used for initial intervention in preventing acute myocarditis from happening.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Kangzhu BPCB0A-3A
Description: The diagnostic test has been used to confirm objective parameters to guide the intervention drug dosages and accessing the risks in sudden death and long term adverse effects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Mobility
Description: The behavioral intervention aimed at reducing the risks of sudden and strong blood flows in the patient's system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril Maleate 10Mg Tab
Description: The intervention aims to reduce the vein flows in Diastolic Blood Pressure, and the risks in blood clot formation and internal vein scratch bleeding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30Mg Ec Cap
Description: The intervention aims to server the allergy-inducing proteins to induce renal hemodialysis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate
Description: Metoprolol Succinate is used to control the cardiac artery flow amounts and stabilize the patient's heart rate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: 200 mg per day is used for supplement with the cardiac interventions.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: d-alpha tocopherol acetate
Description: The 268 mg twice per day dietary healthcare is the patient's usual daily use.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: The 900 mg twice per day dietary healthcare is the patient's usual daily use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release
Description: Duloxetine hydrochloride is used for the patient's neurodiverse conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Superoxide Dismutase
Description: Superoxide Dismutase is used to substitute the missing of antiviral drugs.
Study: NCT05766683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA at a depth of 2mm
Description: One time administration of onabotulinumtoxinA to the corrugator supercilii muscles bilaterally. Dosing dependent on the baseline mass and volume of subject's glabellar muscles as assessed by trained cosmetic dermatologist, accounting for symmetry/asymmetry of the face and can range from 10-50 units. Will be administered at a depth of 2mm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA at a depth of 4mm
Description: One time administration of onabotulinumtoxinA to the corrugator supercilii muscles bilaterally. Dosing dependent on the baseline mass and volume of subject's glabellar muscles as assessed by trained cosmetic dermatologist, accounting for symmetry/asymmetry of the face and can range from 10-50 units. Will be administered at a depth of 4mm
Study: NCT05933135

Intervention type: DRUG
Intervention: Factor XIII Injection
Description: Patients could have had an Factor XIII Injection in clinical routine
Study: NCT05712707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL501 (180 micrograms)
Description: Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL501 (240 micrograms)
Description: Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
Study: NCT05830552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Receving feedback
Description: Receving regular feedback from a health provider

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No regular feedback
Description: No regular feedback from a health provider
Study: NCT06062563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsule and Penpulimab
Description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation by blocking VEGFR, FGFR, PDGFR, and c-Kit simultaneously.~Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC.
Study: NCT04927546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Thirty minutes of aerobic exercise in a treadmill.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Thirty minutes of aerobic exercise in a treadmill.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Thirty minutes of aerobic exercise in a treadmill.
Study: NCT06005688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vepdegestrant
Description: Participants will receive a single dose of Vepdegestrant by mouth in Period 1 and Period 2, with a washout period of at least 20 days between two doses of Vepdegestrant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Participants will receive Carbamazepine by mouth once a day for 19 days in Period 2.
Study: NCT06082934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olverembatinib plus venetoclax and dexamethasone
Description: Olverembatinib: orally every other day at a dose of 40mg Venetoclax: in a daily ramp-up strategy (100 mg d4, 200 mg d5, 400 mg d6-17) Dexamethasone: intravenously 10mg, d1-14, 5mg, d15-28
Study: NCT05712707

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine (Positive Control)
Description: Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
Study: NCT06258226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dosage reduction
Description: The doctor will guide patients to adjust medication dosage once a week in the outpatient clinic. When patients experience withdrawal reactions such as worsening insomnia or anxiety symptoms due to drug reduction, they will be returned to the oral dose before the current reduction, and the dosage will be reduced again after evaluation in the next reduction cycle. The treatment for 4 weeks is one course and 1 course of treatment is required totally.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Description: Auricular acupressure is a non-pharmacological therapy that involves applying acupressure on the surface of points in different parts of the ear. One side of the auricular acupoints will be treated first and the tapes will be kept in place for 3 days. On the fourth day, the tapes on the ear will be removed and new tapes will be applied to the opposite side of the ear. The purpose of replacing tapes is to reduce the adverse events (AEs) that may be caused by long-term stimulation unilaterally. In addition, the participants will be informed to press the tapes by themselves for 3 to 5 minutes vertically and appropriately to achieve the sensation, with a duration of 4 to 5 times a day. The treatment will last for 4 weeks, and the follow-up will be done after 1 month.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham auricular acupressure
Description: Based on the estazolam reduction method in the control group, the acupuncturist will place the same skin-colored adhesive tapes without vaccaria on the auricular points, but these tapes will not be pressed during treatment.
Study: NCT05498649

Intervention type: DEVICE
Intervention: DT1fA
Description: DT1fA contact lenses
Study: NCT04999462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full-fat fermented dairy
Description: Subjects assigned to the full-fat fermented dairy condition will consume 1 serving/d each of full-fat yogurt (plain or reduced sugar varieties) and full-fat fermented cheese.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat fermented dairy
Description: Subjects assigned to the low-fat fermented dairy condition will consume 1 serving/d each of low-fat yogurt (plain or reduced sugar varieties) and lower-fat fermented cheese (e.g., reduced-fat or low-fat fermented cheese).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-dairy, non-fermented foods
Description: Subjects assigned to the control condition will consume 2 servings/d of nondairy, nonfermented foods with a macronutrient composition that is similar to that of the low-fat fermented dairy condition.
Study: NCT04916990

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CARES Intervention
Description: Nurse navigators and masters levels counselors will meet with participants up to 10 times each (10 navigation and 10 counseling) over a 6 month period. The number of sessions will be determined by the length of the patient's treatment. The timing of each session will be guided by a regular assessment to reduce the time from diagnosis to initiation of treatment and the time between subsequent treatments. Sessions will occur at key transition points during treatment to target the factors associated with treatment delays, reduced Quality of Care and poor Patient Reported Outcomes
Study: NCT06406764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric training
Description: Participants undergo a plyometric training program. The plyometric training consists of exercises in the horizontal, lateral, and vertical directions of movement. Exercises are progressively focused on maximal performance with short ground contact (\<250 ms). The training sessions are twice per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control training
Description: Participants continues their regular sports activities without additional plyometric training. The training sessions are twice per week.
Study: NCT05099809

Intervention type: OTHER
Intervention: Hyperthermia
Description: Hyperthermia would be delivered once/twice a week for 60 to 90 minutes depending on patient's tolerance. A shortwave diathermy unit operating at 27.1 MHz would be used to deliver locoregional hyperthermia.
Study: NCT06584188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-inflammatory ketorolac tromethamine
Description: * Intra- radicular anti-inflammatory {ketorolac tromethamine at room temperature}.~* Intra- radicular cold anti-inflammatory {ketorolac tromethamine at 2-5C}.
Study: NCT05640271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Tocilizumab 80 mg IV dose (one time per patient)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 80 mg IV dose (one time per patient)
Study: NCT05565365

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transversalis fascia plane (TFP) block
Description: Patients will receive unilateral US-TFP block with 0.3 mL/kg bupivacaine 0.25% 15 minutes before skin incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane (ESP) Block
Description: Patients will receive unilateral US-ESP block with 0.3 mL/kg bupivacaine 0.25% 15 minutes before skin incision
Study: NCT05310279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GAIMplank
Description: The GAIMplank video game controller will be used to play active video games.
Study: NCT04865159

Intervention type: DRUG
Group type: OTHER
Intervention: Tipifarnib
Description: Cardiac Safety of Tipifarnib
Study: NCT05539066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI health assistant
Description: To study the advantages of AI health assistant management group compared with conventional management group in terms of comprehensive compliance rate, metabolic index level, hypoglycemia incidence rate, and mastery of diabetes related knowledge.
Study: NCT05054075

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Marine liquid and fluids
Description: Marine liquid and fluids extracted from freshwater bivalve of A. cygnea (under very specific conditions)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Marine liquid and fluids
Description: Marine liquid and fluids extracted from freshwater bivalve of A. cygnea (under very specific conditions)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Marine liquid and fluids
Description: Marine liquid and fluids extracted from freshwater bivalve of A. cygnea (under very specific conditions)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Impregnation
Description: SARS / COVID-19 fluid/liquid - impregnation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Impregnation
Description: SARS / COVID-19 fluid/liquid - impregnation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Impregnation
Description: SARS / COVID-19 fluid/liquid - impregnation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Incubation
Description: SARS / COVID-19 fluid-bivalve-incubation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Incubation
Description: SARS / COVID-19 fluid-bivalve-incubation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Incubation
Description: SARS / COVID-19 fluid-bivalve-incubation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Manipulation
Description: Bivalve Manipulation - Stress inducing

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Manipulation
Description: Bivalve Manipulation - Stress inducing

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Manipulation
Description: Bivalve Manipulation - Stress inducing

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Refrigeration
Description: Refrigerated fluid to check for maintained response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Refrigeration
Description: Refrigerated fluid to check for maintained response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Refrigeration
Description: Refrigerated fluid to check for maintained response
Study: NCT05020951

Intervention type: OTHER
Intervention: Medidata RAVE
Description: Data collection done exclusively through Medidata Rave. Medidata Rave is a clinical data management system being used for data collection for this trial/study. Access to the trial in Rave is controlled through the CTEP-IAM system and role assignments.
Study: NCT05776940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules combined with Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab
Description: Naive al amyloidosis patients receive Bortezomib+Dexamethasone, Bortezomib+Dexamethasone+Daratumumab or single Daratumumab therapy combined with Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules(250mg/time, bid,up to 3 months).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab
Description: Naive al amyloidosis patients receive Bortezomib+Dexamethasone, Bortezomib+Dexamethasone+Daratumumab or single Daratumumab therapy without any probiotics (Blank Control).